Clinical and radiological evaluation of an osseous xenograft for the treatment of infrabony defects.
To evaluate the effectiveness of demineralized bone matrix (DMBM), an osteoconductive and osteoinductive graft material, as a bone graft for the treatment of osseous defects, both clinically and radiographically. The effectiveness of DMBM was assessed at 40 sites in 30 patients who had infrabony defects. Grafted test sites were compared with control sites treated with open-flap debridement. Significant improvement in all variables was found, including reduction of probing depth, and gain in clinical attachment level and bone fill for test and control sites at 3 months and 6 months postoperatively. For test sites, reduction of probing depth was 2.80 mm at 3 months and 4.05 mm at 6 months, and for control sites, 1.75 mm at 3 months and 2.65 mm at 6 months. Gain in the level of clinical attachment for test sites was 2.80 mm at 3 months and 4.00 mm at 6 months; for control sites, this gain was 1.75 mm at 3 months and 2.60 mm at 6 months. The mean amount of defect resolution was 2.02 mm and 3.27 mm for test sites and 0.82 mm and 1.17 mm for control sites, at 3 months and 6 months, respectively. The mean percentage of defect resolution was 37.1% and 56.5% for test sites compared with 20.5% and 28.6% for control sites, at3 months and 6 months, respectively. DMBM improves healing outcomes, namely, reduction of probing depth, resolution of osseous defects and gain in clinical attachment, compared with open flap debridement.